1 day Ago By Defense World Staff
Renaissance Technologies LLC raised its position in shares of Century Therapeutics, Inc. (NASDAQ:IPSC – Free Report) by 146.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC).
The institutional investor owned 1,202,885 shares of the company’s stock after buying an additional 714,685 shares during the quarter. Renaissance Technologies LLC owned about 1.41% of Century Therapeutics worth $1,215,000 as of its most recent SEC filing.
A number of other large investors have also added to or reduced their stakes in the company. Geode Capital Management LLC grew its holdings in shares of Century Therapeutics by 2.4% in the fourth quarter.
Geode Capital Management LLC now owns 991,595 shares of the company’s stock valued at $1,002,000 after purchasing an additional 23,413 shares in the last quarter. State Street Corp grew its stake in shares of Century Therapeutics by 7.4% in the 3rd quarter.
State Street Corp now owns 836,914 shares of the company’s stock worth $1,431,000 after buying an additional 57,323 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Century Therapeutics by 127.
5% in the 4th quarter. JPMorgan Chase & Co. now owns 163,189 shares of the company’s stock worth $165,000 after buying an additional 91,468 shares during the last quarter.
Barclays PLC lifted its holdings in shares of Century Therapeutics by 283.6% in the 3rd quarter. Barclays PLC now owns 61,945 shares of the company’s stock valued at $106,000 after acquiring an additional 45,797 shares during the last quarter.
Finally, Sei Investments Co. purchased a new position in Century Therapeutics in the fourth quarter worth about $53,000. Institutional investors own 50.
20% of the company’s stock. Century Therapeutics Price PerformanceCentury Therapeutics stock opened at $0.50 on Wednesday.
The stock has a market cap of $43.38 million, a price-to-earnings ratio of -0.27 and a beta of 1.
83. The firm has a 50-day moving average of $0.55 and a two-hundred day moving average of $0.
94. Century Therapeutics, Inc. has a 1 year low of $0.
34 and a 1 year high of $3.70. Century Therapeutics (NASDAQ:IPSC – Get Free Report) last announced its quarterly earnings data on Wednesday, March 19th.
The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.
02. The company had revenue of $4.18 million for the quarter, compared to analysts’ expectations of $0.
67 million. Century Therapeutics had a negative return on equity of 61.66% and a negative net margin of 4,837.
73%. Research analysts expect that Century Therapeutics, Inc. will post -1.
61 earnings per share for the current year. Wall Street Analyst Weigh InA number of equities analysts have recently commented on IPSC shares. HC Wainwright dropped their target price on Century Therapeutics from $5.
00 to $2.00 and set a “buy” rating for the company in a report on Thursday, April 3rd. Chardan Capital lowered their target price on shares of Century Therapeutics from $11.
00 to $7.00 and set a “buy” rating for the company in a report on Monday, March 24th. Guggenheim reiterated a “buy” rating on shares of Century Therapeutics in a report on Friday, March 28th.
Finally, Piper Sandler dropped their target price on Century Therapeutics from $4.00 to $2.00 and set an “overweight” rating for the company in a research report on Thursday, March 20th.
Five research analysts have rated the stock with a buy rating, According to MarketBeat, Century Therapeutics has an average rating of “Buy” and a consensus price target of $4.40.View Our Latest Analysis on Century TherapeuticsAbout Century Therapeutics (Free Report)Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies.
Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.Featured ArticlesFive stocks we like better than Century TherapeuticsLarge Cap Stock Definition and How to InvestDon’t Be Fooled by the Bounce: The Market Storm Isn’t Over YetManufacturing Stocks InvestingCoca-Cola Company Stock Can Bubble to New Highs This YearP/E Ratio Calculation: How to Assess Stocks3 Stocks Lifting 2025 Guidance Despite Market Jitters.
